Immuron Limited
IMRNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Immuron Limited focuses on Biotechnology services and products. Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. At a $7.7M market cap, Immuron Limited ranks as a micro-cap company within healthcare. It operates through two segments, Research and Development; and Hyper-immune Products.
Market Cap
$7.7M
Beta
0.47
P/E (TTM)
—
P/E (Fwd)
-95.35
EPS (TTM)
$-0.34
EPS (Fwd)
$-0.01
ROE
-38.3%
ROA
-19.1%
Cash
$9.0M
Total Debt
$189,543
Free CF
-$2.1M
52W Change
-55.6%
Annual Financials
Cash vs Debt
Where IMRN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, IMRN finished 10.28% below its 150-day moving average ($1.07) and 4.95% below its 200-day moving average ($1.01). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IMRN overbought or oversold?
At the October 20, 2026 close, IMRN's RSI(14) was 12.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $9.0M in cash comfortably exceeding the $190K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$2.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -38.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $1.8M (2023) to $7.7M (2026), reflecting a 327% increase over the period.
The relatively low beta of 0.47 suggests IMRN is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, IMRN has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing IMRN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.